Compare Merck & Co., Inc. (MRK) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wheaton Precious Metals Corp — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Wheaton Precious Metals Corp trades at $110.88 (market cap $46.54B). The key difference: Merck & Co., Inc. is far larger — about 6.6× Wheaton Precious Metals Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | WPM | |
|---|---|---|
Market Cap | $307.25B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $129.52 | $165.72 |
52-Week Low | $77.60 | $91.00 |
Enterprise Value | $350.66B | $44.39B |
Dividend Yield | 2.73% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Wheaton Precious Metals (WPM) trades at $109.96, up 5.55% today, with a bearish technical signal but strong fundamentals. The company reported record revenue of $2.31B in 2025, net income of $1.47B, and has beaten earnings estimates for three consecutive quarters. Operating cash flow surged to $1.90B in 2025, supporting a positive outlook.
WPM offers growth potential with an 80% analyst buy rating and a consensus price target of $161.75, implying significant upside. Risks include exposure to precious metal price volatility and a high P/E ratio of 26.14. The stock's current discount to target presents a buying opportunity for long-term investors, contingent on stable metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
